A transcutaneous acupoint electrical stimulation device for simulating the effect of lung-regulating and intestine-nourishing needle method

Abstract

This invention relates to the field of biomedical industry technology, specifically to a transcutaneous acupoint electrical stimulation device that simulates the effects of acupuncture for regulating the lungs and benefiting the intestines. Before the patient's skin keratinocytes reach a steady-state conductive state, the device employs voltage boost control. The specific method includes: calculating the overshoot risk value at the next sampling time; if the overshoot risk value at the next sampling time is greater than or equal to a set low-risk threshold and less than a set high-risk threshold, then the voltage increment at the next sampling time is set to a standard voltage increment; if the overshoot risk value is greater than or equal to the set high-risk threshold, then the voltage increment at the next sampling time is set to a high-risk voltage increment, and the high-risk voltage increment is set to be less than the standard voltage increment; if the overshoot risk value is less than the set low-risk threshold, then the voltage increment at the next sampling time is set to a low-risk voltage increment, and the low-risk voltage increment is greater than or equal to the standard voltage increment. A smaller voltage increment is used for high-risk cases, and a larger voltage increment is used for low-risk cases.

Description

Technical Field

[0001] This invention relates to the field of biomedical industry technology, specifically to a transcutaneous acupoint electrical stimulation device that simulates the effects of acupuncture for regulating the lungs and benefiting the intestines. Background Technology

[0002] Transcutaneous electrical stimulation (TEAS) devices input specific waveform current pulses into the human body through electrodes on the body surface to simulate traditional Chinese medicine acupuncture and massage. It is an intelligent physical therapy device that combines Chinese and Western medicine and is widely used in the fields of postoperative rehabilitation and pain management.

[0003] The core acupoints of the Lung-Regulating and Intestine-Benefiting Acupuncture Technique (involving the Lung Meridian of Hand-Taiyin, the Large Intestine Meridian, and related Shu-Mu points) exhibit a severe polarization in surface skin resistance. For example, acupoints such as Feishu, Dachangshu, and Tianshu are located on the delicate and tender skin of the trunk or inner upper arm, resulting in lower surface skin resistance. In contrast, acupoints such as Hegu, Taiyuan, and Shaoshang are located on the hand, where daily activities are frequent, leading to the formation of a thicker, highly resistive stratum corneum. Acupoints such as Quchi and Chize are located at the elbow joint, which not only experience more friction during daily activities, making them prone to forming highly resistive stratum corneum, but also lack glands nearby, resulting in drier surface skin and further increasing surface skin resistance.

[0004] When applying electrical stimulation to high-impedance acupoints, the voltage across the electrodes needs to be increased to exceed the tolerance voltage of the stratum corneum of the skin at the acupoint. This causes the stratum corneum to undergo an electroporation effect, reducing its impedance and thus stimulating the acupoint. However, because the impedance of the stratum corneum decreases instantaneously when the electroporation effect occurs, the current spike becomes too large, causing a strong transient stinging sensation in the patient and reducing patient compliance.

[0005] In order to solve the problem of excessive current spikes, existing technologies usually use circuit limiting methods to limit the current spikes. However, this method will cause the actual output waveform to be "cropped", so that the total charge (energy) injected into the acupoints is lower than the design requirements of the treatment plan, thereby reducing the effectiveness of electrical stimulation. Summary of the Invention

[0006] To address the aforementioned technical problems, the present invention aims to provide a transcutaneous acupoint electrical stimulation device that simulates the effects of acupuncture for regulating the lungs and benefiting the intestines. The specific technical solution adopted is as follows: This invention discloses a transcutaneous acupoint electrostimulation device for simulating the effects of acupuncture for regulating the lungs and benefiting the intestines. The device includes a data acquisition module, a processing module, and an electrostimulation module. The data acquisition module acquires voltage and current data between the electrodes of the electrostimulation module and sends this data to the processing module. The processing module controls the voltage between the electrodes of the electrostimulation module based on the received voltage and current data. The control method includes: Determine whether the patient's skin keratin is in a steady-state conductive state at the current sampling time. If it is, use steady-state mode to control the voltage between the electrodes of the electrical stimulation module at the next sampling time; otherwise, use boost mode to control the voltage between the electrodes of the electrical stimulation module at the next sampling time. The control methods for boost mode include: The overshoot risk value at the next sampling moment is calculated based on the voltage and current data between the electrodes of the electrical stimulation module. If the overshoot risk value at the next sampling time is greater than or equal to the set low-risk threshold and less than the set high-risk threshold, then the voltage increment at the next sampling time is set as the standard voltage increment. If the overshoot risk value at the next sampling time is greater than or equal to the set high-risk threshold, then the voltage increment at the next sampling time is set as the high-risk voltage increment, and the high-risk voltage increment is set to be less than the standard voltage increment. If the overshoot risk value at the next sampling time is less than the set low-risk threshold, then the voltage increment at the next sampling time is set as the low-risk voltage increment, and the low-risk voltage increment is greater than or equal to the standard voltage increment.

[0007] In conjunction with the first aspect above, in some possible implementations, the low-risk voltage increment is obtained based on the sum of the standard voltage increment and the accumulated voltage at the current sampling time; The methods for calculating the accumulated voltage at the current sampling time include: Calculate the difference between the standard voltage increment and the voltage increment at each sampling time up to the current sampling time in boost mode, and sum the differences to obtain the accumulated voltage at the current sampling time.

[0008] In conjunction with the first aspect above, among some possible implementations, the method for obtaining the low-risk voltage increment based on the sum of the standard voltage increment and the accumulated voltage is as follows: The smaller value between the sum of the standard voltage increment and the accumulated voltage, and the maximum voltage increment of the electrical stimulation module, is taken as the low-risk voltage increment.

[0009] In conjunction with the first aspect mentioned above, among some possible implementations, the methods for calculating the overshoot risk value at the next sampling time include: Based on the voltage and current data between the electrodes of the electrical stimulation module, the equivalent impedance of the patient's skin is calculated, and then the rate of change of the equivalent impedance of the patient's skin is calculated. The acceleration of the change in the patient's skin equivalent impedance at the current sampling time is calculated based on the rate of change of the patient's skin equivalent impedance. Based on the rate of change of the patient's skin equivalent impedance and the acceleration of the change of the patient's skin equivalent impedance at the current sampling time, the rate of change of the patient's skin equivalent impedance at the next sampling time is predicted; The overshoot risk value for the next sampling time is obtained based on the rate of change of the patient's skin equivalent impedance at the next sampling time.

[0010] In conjunction with the first aspect above, among some possible implementations, methods for obtaining the overshoot risk value at the next sampling time based on the rate of change of the patient's skin equivalent impedance at the next sampling time include: Based on the voltage and current data between the electrodes of the electrical stimulation module, the electrical power received by the patient's skin at the current sampling moment is calculated. By combining the rate of change of the patient's skin equivalent impedance at the next sampling time with the electrical power experienced by the patient's skin at the current sampling time, the overshoot risk value at the next sampling time is obtained.

[0011] In conjunction with the first aspect mentioned above, among some possible implementation methods, the methods for determining whether the patient's skin keratinocytes are in a steady-state conductive state at the current sampling time include: Determine whether the patient's skin equivalent impedance is stable at the current sampling time; Determine whether the current meets the standard at the current sampling time; If the patient's skin equivalent impedance is stable and the current meets the standard at the current sampling time, then the patient's skin keratin is determined to be in a steady-state conductive state at the current sampling time; otherwise, the patient's skin keratin is determined to be in a non-steady-state conductive state at the current sampling time.

[0012] In conjunction with the first aspect mentioned above, among some possible implementation methods, the methods for determining whether the patient's skin equivalent impedance is stable at the current sampling time include: If the absolute value of the rate of change of the patient's skin equivalent impedance at the current sampling time is less than or equal to the steady-state threshold, and the duration exceeds the set time, then the patient's skin equivalent impedance at the current sampling time is determined to be stable; otherwise, the patient's skin equivalent impedance at the current sampling time is determined to be unstable.

[0013] In conjunction with the first aspect mentioned above, among some possible implementation methods, the methods for determining whether the current at the current sampling moment meets the standard include: If the current at the current sampling moment is greater than or equal to the set proportion of the target treatment current, then the current at the current sampling moment is determined to meet the standard; otherwise, the current at the current sampling moment is determined to not meet the standard.

[0014] In conjunction with the first aspect mentioned above, in some possible implementations, the steady-state mode employs constant current proportional-integral control, and the constant current target is the target therapeutic current.

[0015] In conjunction with the first aspect mentioned above, among some possible implementation methods, the specific methods of constant current proportional-integral control include: The error difference is obtained by subtracting the current error from the previous sampling time from the current error at the current sampling time; the error difference is then multiplied by a proportional coefficient to obtain the proportional adjustment term. The current error at the current sampling moment is multiplied by the integral coefficient to obtain the integral adjustment term; By combining the proportional adjustment term and the integral adjustment term, the voltage increment at the next sampling moment is obtained, and then the voltage between the electrodes of the electrical stimulation module at the next sampling moment is controlled.

[0016] This invention has the following beneficial effects: It divides the voltage control mode between the electrodes of the electrostimulation module into a boost mode and a steady-state mode. The boost mode is used before the patient's skin keratin is in a steady-state conductive state, continuously increasing the voltage. Furthermore, in the boost mode, the invention also calculates the overshoot risk value at the next sampling moment to assess the risk of a current spike causing a stinging sensation in the patient. When the risk is high, the voltage rise rate is slowed to avoid current spikes. When the risk is low, the voltage rise rate is increased to compensate for the energy loss caused by slowing the voltage rise rate when the risk is high. This increases the energy injected into the patient's acupoints, preventing a decrease in acupoint injection energy due to reducing current spikes, thus improving the therapeutic effect. Attached Figure Description

[0017] To more clearly illustrate the technical solutions and advantages in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0018] Figure 1 This is a flowchart illustrating the process of determining the voltage between the electrodes of the electrical stimulation module according to an embodiment of the present invention. Detailed Implementation

[0019] To clearly illustrate the technical features of this solution, the invention will be described in detail below through specific embodiments and in conjunction with the accompanying drawings.

[0020] Embodiments of the present invention will now be described in more detail with reference to the accompanying drawings. While some embodiments of the invention are shown in the drawings, it should be understood that the invention can be implemented in various forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided to provide a more thorough and complete understanding of the invention. It should be understood that the accompanying drawings and embodiments are for illustrative purposes only and are not intended to limit the scope of protection of the invention.

[0021] It should be understood that the various steps described in the method embodiments of the present invention may be performed in different orders and / or in parallel. Furthermore, the method embodiments may include additional steps and / or omit the steps shown. The scope of the present invention is not limited in this respect.

[0022] The present invention provides a transcutaneous acupoint electrical stimulation device for simulating the effects of acupuncture for regulating the lungs and benefiting the intestines, comprising a data acquisition module, a processing module, and an electrical stimulation module.

[0023] The acquisition module is used to sample the voltage and current data (hereinafter referred to as voltage sampling data and current sampling data) between the electrodes of the electrical stimulation module in real time at the current sampling moment according to a set sampling frequency, and send them to the processing module. The sampling frequency is set to 1kHz to 10kHz. In this embodiment, 1kHz is used as an example, and the corresponding acquisition interval is 1ms.

[0024] The processing module is used to determine the output voltage between the electrodes of the electrical stimulation module based on the received voltage and current sampling data, and to control the electrical stimulation module in real time according to the voltage.

[0025] The process flow for determining the voltage between the electrodes of the electrical stimulation module by the processing module is as follows: Figure 1 As shown, it includes the following steps: Step 1: Preprocess the actual voltage and current data, and based on the preprocessed voltage and current data, calculate the patient's skin equivalent impedance data, and then calculate the rate of change of the patient's skin equivalent impedance at the current sampling time. Specific methods include: 1.1) Preprocess the voltage and current data to obtain preprocessed voltage and current data.

[0026] In this embodiment, the preprocessing includes moving average filtering. Specifically, the method includes: setting a fixed time window width, and performing average filtering on the voltage or current sampled data for each time window to obtain the preprocessed voltage or current data at the end of the time window; continuously sliding the time window and repeating the average filtering process to obtain the preprocessed voltage and current data at each sampling time.

[0027] In this embodiment, the fixed time window width is 5ms, and each time window includes 5 voltage or current data points. The corresponding average filtering method includes: In the formula, Indicates the first Each sampling time, Indicates the first Each sampling time, For the preprocessed first Current at each sampling time, For the first Current data sampled at each sampling time. This refers to the number of sampling times contained within a fixed time window. In this embodiment... =5.

[0028] In the formula, For the preprocessed first Voltage at each sampling time, For the first Voltage data collected at each sampling time.

[0029] 1.2) Calculate the patient’s skin equivalent impedance based on the preprocessed voltage and current data.

[0030] Because the current data is at a very low value during the initial stage of the electrical pulse initiation or in cases of poor electrode contact, directly calculating the patient's skin equivalent impedance is not only inaccurate but also leads to data overflow, affecting subsequent processing. To address this issue, this embodiment sets a preset lower current limit. ,use and The sum of these values ​​is used to calculate the patient's skin equivalent impedance, expressed by the following formula: In the formula, Indicates the first The patient's skin equivalent impedance at each sampling time. In this embodiment, a preset lower current limit is used. This is the minimum current that the human body can perceive, such as 0.1mA.

[0031] 1.3) Based on the patient's skin equivalent impedance data, calculate the rate of change of the patient's skin equivalent impedance at the current sampling time.

[0032] Specific calculation methods include: In the formula, At the current sampling time, The previous sampling time (referred to as the previous sampling time) is the current sampling time. The sampling interval is... The equivalent impedance of the patient's skin at the previous sampling time. The patient's skin equivalent impedance at the current sampling time. This represents the rate of change of the patient's skin equivalent impedance at the current sampling time. A value greater than 0 indicates a decreasing rate, and a value less than 0 indicates an increasing rate.

[0033] Step 2: Based on the rate of change of the patient's skin equivalent impedance and the current at the current sampling time, determine whether the patient's skin keratin is in a steady-state conduction state at the current sampling time, and then determine the control mode for the next sampling time.

[0034] Specific methods include: 2.1) Determine whether the patient's skin equivalent impedance is stable at the current sampling time.

[0035] If the absolute value of the rate of change of the patient's skin equivalent impedance at the current sampling time is less than or equal to the steady-state threshold, and the duration exceeds the set time, then the patient's skin equivalent impedance at the current sampling time is determined to be stable; otherwise, the patient's skin equivalent impedance at the current sampling time is determined to be unstable. The formula is expressed as: In the formula, As the steady-state threshold, in this embodiment , The duration during which the absolute value of the rate of change of the patient's skin equivalent impedance is less than or equal to the steady-state threshold. In this embodiment, the set time is 5ms.

[0036] 2.2) Determine whether the current at the current sampling time meets the standard.

[0037] If the current at the current sampling moment is greater than or equal to a set proportion of the target treatment current, then the current at the current sampling moment is determined to meet the standard; otherwise, the current at the current sampling moment is determined to not meet the standard. The formula is expressed as follows: In the formula, Targeted therapeutic current, To set the ratio, its value is usually in the range of 0.7 to 0.9. In this embodiment... .

[0038] 2.3) Determine whether the patient's skin keratin is in a steady-state conductive state at the current sampling time. If it is in a steady-state conductive state, use the steady-state control mode to control the output voltage between the electrodes of the electrical stimulation module at the next sampling time. Otherwise, use the boost mode to control the output voltage between the electrodes of the electrical stimulation module at the next sampling time.

[0039] In this embodiment, the method for determining whether the patient's skin keratinocytes are in a steady-state conductive state at the current sampling time includes: If the patient's skin equivalent impedance is stable and the current meets the standard at the current sampling time, it is determined that the patient's skin keratin is in a steady-state conductive state at the current sampling time; otherwise, it is determined that the patient's skin keratin is not in a steady-state conductive state at the current sampling time.

[0040] During a treatment, the patient's skin keratin has high impedance and low current at the beginning stage, and the patient's skin keratin is not in a steady-state conductive state. Therefore, the voltage boost mode is first used to control the output voltage between the electrodes of the electrostimulation module. The voltage is gradually increased until the patient's skin keratin produces an electroporation effect, the impedance decreases, the current increases and reaches the target. Then, the steady-state control mode is switched to control the output voltage between the electrodes of the electrostimulation module.

[0041] Step 3: Use boost mode to control the output voltage between the electrodes of the electrical stimulation module at the next sampling time.

[0042] Specific methods include: 3.1) Based on the preprocessed voltage and current data, calculate the electrical power delivered to the patient's skin at the current sampling moment. The specific calculation method includes: In the formula, This represents the electrical power delivered to the patient's skin at the current sampling moment. It measures the energy level applied to the patient's skin by the electrical stimulation module. The higher the value, the stronger the impact during a sudden impedance drop and current overshoot. The voltage at the current sampling time. This represents the current at the current sampling moment.

[0043] 3.2) Based on the rate of change of the patient's skin equivalent impedance at the current sampling time and the rate of change of the patient's skin equivalent impedance at the previous sampling time, calculate the acceleration of the change of the patient's skin equivalent impedance at the current sampling time.

[0044] Specific calculation methods include: In the formula, The rate of change of the patient's skin equivalent impedance at the previous sampling time. This represents the acceleration of the change in the patient's skin equivalent impedance at the current sampling time. The equivalent impedance of the patient's skin at the time two sampling points prior. The equivalent impedance of the patient's skin at the previous sampling time.

[0045] 3.3) Based on the rate of change of the patient's skin equivalent impedance at the current sampling time and the acceleration of the change of the patient's skin equivalent impedance at the current sampling time, predict the rate of change of the patient's skin equivalent impedance at the next sampling time.

[0046] In the formula, For the next sampling time, This is the predicted rate of change in the patient's skin equivalent impedance at the next sampling time.

[0047] 3.4) By combining the rate of change of the patient's skin equivalent impedance at the next sampling time with the electrical power borne by the patient's skin at the current sampling time, the overshoot risk value at the next sampling time is obtained.

[0048] In the formula, This represents the overshoot risk value for the next sampling time. To perform the maximum value operation, when A value less than 0 indicates that the patient's skin equivalent impedance increases rather than drops suddenly at the next sampling time, preventing overshoot and eliminating the risk of overshoot. Therefore, the overshoot risk value is 0 at this time. The reference value for the electrical power received by the patient's skin is a very small value greater than 0, which is 1 milliwatt in this embodiment. This is used to prevent the risk of overshoot from being zero when the electrical power received by the patient's skin at the current sampling time is zero. This indicates normalization processing. In this embodiment, maximum and minimum value normalization processing is used, where the minimum value is set to 0, and the maximum value is set to the ratio of the maximum electrical power that the patient's skin can withstand (e.g., 5W, or 5000mW) to the rate of change of the patient's skin's equivalent impedance in history (e.g., 1000mW). The product of ) if the current patient If the value is greater than the maximum value, its normalization result is set to 1.

[0049] 3.5) Based on the overshoot risk value at the next sampling time, determine the voltage increment at the next sampling time, and then control the output voltage between the electrodes of the electrical stimulation module.

[0050] If the overshoot risk value at the next sampling time If the risk level is greater than or equal to the set low-risk threshold and less than the set high-risk threshold, then the follow mode will be executed.

[0051] In follow mode, the voltage increment at the next sampling time is set to the standard voltage increment. The formula is as follows: In the formula, This represents the voltage increment at the next sampling time. For standard voltage increments, The standard voltage rise slope (i.e., standard voltage rise rate) is 0.02V / ms in this embodiment.

[0052] If the overshoot risk value at the next sampling time If the risk level is greater than or equal to the set high-risk threshold, then the avoidance mode will be executed.

[0053] Overshoot risk value at the next sampling time If the voltage is greater than or equal to the set high-risk threshold, it indicates that the patient's skin stratum corneum is highly likely to experience electroporation at the next sampling time, causing a sharp drop in the patient's skin's equivalent impedance. If the voltage is further increased at this point, it will exacerbate the current overshoot problem. The avoidance mode is used to prevent this current overshoot from worsening. The specific control method for the avoidance mode is as follows: The voltage increment at the next sampling time is set as the high-risk voltage increment, which is less than the standard voltage increment. In this embodiment, the high-risk voltage increment is set as a preset lower limit of voltage increment. This is to ensure that the voltage at the next sampling moment is not too high, thereby reducing the severity of current overshoot. Less than In this embodiment, the preset lower limit of voltage increment is 0. The formula is expressed as: Because the voltage increment is set to a preset lower limit in obstacle avoidance mode. Failed to follow standard voltage increment This setup creates a voltage increment difference between the two, resulting in a certain loss of energy injected into the current patient's acupoint. To compensate for this energy loss when the risk of overshoot is low, this invention accumulates the voltage difference between the standard voltage increment and the voltage increment at each sampling time up to the current sampling time in boost mode to obtain the accumulated voltage (i.e., the accumulated unexecuted voltage increment). The formula is as follows: In the formula, This is the accumulated voltage at the current sampling moment. This is the accumulated voltage at the previous sampling time. This represents the difference between the standard voltage increment and the voltage increment at the current sampling time.

[0054] To prevent damage caused by poor electrode contact or prolonged high resistance of the skin... The problem of infinite accumulation is addressed in this implementation method. A voltage limiting process is applied when the accumulated voltage exceeds or equals the upper limit of the safe accumulated voltage. At that time, Limiting to the upper limit of safe backlog voltage In this embodiment, the upper limit of the safe backlog voltage is... It is 5V.

[0055] If the overshoot risk value at the next sampling time If the risk level is below the set low-risk threshold, the compensation mode will be executed.

[0056] In compensation mode, the voltage increment at the next sampling time is set as the low-risk voltage increment, which is greater than or equal to the standard voltage increment. The value is used to consume the accumulated voltage.

[0057] In this embodiment, the low-risk voltage increment is no longer a fixed value, but is determined based on the standard voltage increment and the accumulated voltage at the current sampling time.

[0058] In this embodiment, the method for determining low-risk voltage increments includes: In the formula, This represents the low-risk voltage increment at the next sampling time. The maximum voltage increment is equal to the maximum voltage increase rate set by the manufacturer for the electrical stimulation device multiplied by the sampling interval. . This indicates the operation of finding the minimum value.

[0059] The formula shows that, within the allowable upper limit of voltage increment, the voltage increment at the next sampling moment should be able to compensate for all the accumulated voltage at the current sampling moment.

[0060] Based on the voltage increment at the next sampling time and the voltage at the current sampling time, the voltage at the next sampling time is obtained, and then the output voltage between the electrodes of the electrical stimulation module is controlled.

[0061] In the formula, The voltage at the current sampling time. This represents the voltage at the next sampling time.

[0062] In this embodiment, the low-risk threshold ranges from 0.35 to 0.45, and is set to 0.35. The high-risk threshold ranges from 0.75 to 0.85, and is set to 0.75 in this embodiment.

[0063] Step 4: Use steady-state mode to control the output voltage between the electrodes of the electrical stimulation module at the next sampling time.

[0064] In this embodiment, a constant current PI (proportional-integral) control method is used for control in steady-state control mode. The specific method includes: Calculate the current error at the current sampling time and the current error at the previous sampling time.

[0065] In the formula, This represents the current error at the current sampling moment. This represents the current error at the previous sampling time.

[0066] Calculate the voltage increment at the next sampling time based on the current error at the current sampling time and the current error at the previous sampling time.

[0067] In the formula, This represents the voltage increment at the next sampling time. This represents the current error at the previous sampling time. This is the proportionality coefficient. is the integral coefficient. For proportional adjustment items, This is an integral adjustment term.

[0068] Based on the voltage increment at the next sampling time and the voltage at the current sampling time, the voltage at the next sampling time is obtained, and then the output voltage between the electrodes of the electrical stimulation module is controlled.

[0069] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention, and should all be included within the protection scope of the present invention.

Claims

1. A transcutaneous acupoint electrostimulation device simulating the effects of acupuncture for regulating the lungs and benefiting the intestines, comprising a data acquisition module, a processing module, and an electrostimulation module, wherein the data acquisition module acquires voltage and current data between the electrodes of the electrostimulation module and sends it to the processing module, and the processing module controls the voltage between the electrodes of the electrostimulation module based on the received voltage and current data, characterized in that... Control methods include: Determine whether the patient's skin keratin is in a steady-state conductive state at the current sampling time. If it is, use steady-state mode to control the voltage between the electrodes of the electrical stimulation module at the next sampling time; otherwise, use boost mode to control the voltage between the electrodes of the electrical stimulation module at the next sampling time. The control methods for boost mode include: The overshoot risk value at the next sampling moment is calculated based on the voltage and current data between the electrodes of the electrical stimulation module. If the overshoot risk value at the next sampling time is greater than or equal to the set low-risk threshold and less than the set high-risk threshold, then the voltage increment at the next sampling time is set as the standard voltage increment. If the overshoot risk value at the next sampling time is greater than or equal to the set high-risk threshold, then the voltage increment at the next sampling time is set as the high-risk voltage increment, and the high-risk voltage increment is set to be less than the standard voltage increment. If the overshoot risk value at the next sampling time is less than the set low-risk threshold, then the voltage increment at the next sampling time is set as the low-risk voltage increment, and the low-risk voltage increment is greater than or equal to the standard voltage increment.

2. The transcutaneous acupoint electrical stimulation device for simulating the effects of acupuncture for regulating the lungs and benefiting the intestines, as described in claim 1, is characterized in that... The low-risk voltage increment is obtained based on the sum of the standard voltage increment and the accumulated voltage at the current sampling time; The methods for calculating the accumulated voltage at the current sampling time include: Calculate the difference between the standard voltage increment and the voltage increment at each sampling time up to the current sampling time in boost mode, and sum the differences to obtain the accumulated voltage at the current sampling time.

3. The transcutaneous acupoint electrical stimulation device for simulating the effects of acupuncture for regulating the lungs and benefiting the intestines, as described in claim 2, is characterized in that... The method for obtaining the low-risk voltage increment based on the sum of the standard voltage increment and the accumulated voltage is as follows: The smaller value between the sum of the standard voltage increment and the accumulated voltage, and the maximum voltage increment of the electrical stimulation module, is taken as the low-risk voltage increment.

4. The transcutaneous acupoint electrical stimulation device for simulating the effects of acupuncture for regulating the lungs and benefiting the intestines, as described in claim 1, is characterized in that... The methods for calculating the overshoot risk value at the next sampling time include: Based on the voltage and current data between the electrodes of the electrical stimulation module, the equivalent impedance of the patient's skin is calculated, and then the rate of change of the equivalent impedance of the patient's skin is calculated. The acceleration of the change in the patient's skin equivalent impedance at the current sampling time is calculated based on the rate of change of the patient's skin equivalent impedance. Based on the rate of change of the patient's skin equivalent impedance and the acceleration of the change of the patient's skin equivalent impedance at the current sampling time, the rate of change of the patient's skin equivalent impedance at the next sampling time is predicted; The overshoot risk value for the next sampling time is obtained based on the rate of change of the patient's skin equivalent impedance at the next sampling time.

5. The transcutaneous acupoint electrical stimulation device for simulating the effects of acupuncture for regulating the lungs and benefiting the intestines, as described in claim 4, is characterized in that... Methods for obtaining the overshoot risk value at the next sampling time based on the rate of change of the patient's skin equivalent impedance at the next sampling time include: Based on the voltage and current data between the electrodes of the electrical stimulation module, the electrical power received by the patient's skin at the current sampling moment is calculated. By combining the rate of change of the patient's skin equivalent impedance at the next sampling time with the electrical power experienced by the patient's skin at the current sampling time, the overshoot risk value at the next sampling time is obtained.

6. The transcutaneous acupoint electrical stimulation device for simulating the effects of acupuncture for regulating the lungs and benefiting the intestines, as described in claim 1, is characterized in that... Methods for determining whether the patient's skin keratinocytes are in a steady-state conductive state at the current sampling time include: Determine whether the patient's skin equivalent impedance is stable at the current sampling time; Determine whether the current meets the standard at the current sampling time; If the patient's skin equivalent impedance is stable and the current meets the standard at the current sampling time, then the patient's skin keratin is determined to be in a steady-state conductive state at the current sampling time; otherwise, the patient's skin keratin is determined to be in a non-steady-state conductive state at the current sampling time.

7. The transcutaneous acupoint electrical stimulation device for simulating the effects of acupuncture for regulating the lungs and benefiting the intestines according to claim 6, characterized in that, Methods for determining whether the patient's skin equivalent impedance is stable at the current sampling time include: If the absolute value of the rate of change of the patient's skin equivalent impedance at the current sampling time is less than or equal to the steady-state threshold, and the duration exceeds the set time, then the patient's skin equivalent impedance at the current sampling time is determined to be stable; otherwise, the patient's skin equivalent impedance at the current sampling time is determined to be unstable.

8. The transcutaneous acupoint electrical stimulation device for simulating the effects of acupuncture for regulating the lungs and benefiting the intestines according to claim 6, characterized in that, Methods for determining whether the current meets the standard at the current sampling moment include: If the current at the current sampling moment is greater than or equal to the set proportion of the target treatment current, then the current at the current sampling moment is determined to meet the standard; otherwise, the current at the current sampling moment is determined to not meet the standard.

9. The transcutaneous acupoint electrical stimulation device for simulating the effects of acupuncture for regulating the lungs and benefiting the intestines according to claim 1, characterized in that, The steady-state mode employs constant current proportional-integral control, with the constant current target being the target therapeutic current.

10. The transcutaneous acupoint electrical stimulation device for simulating the effects of acupuncture for regulating the lungs and benefiting the intestines according to claim 9, characterized in that, Specific methods for constant current proportional-integral control include: The error difference is obtained by subtracting the current error from the previous sampling time from the current error at the current sampling time; the error difference is then multiplied by a proportional coefficient to obtain the proportional adjustment term. The current error at the current sampling moment is multiplied by the integral coefficient to obtain the integral adjustment term; By combining the proportional adjustment term and the integral adjustment term, the voltage increment at the next sampling moment is obtained, and then the voltage between the electrodes of the electrical stimulation module at the next sampling moment is controlled.

Images